AbbVie: Virus Diseases trials

The registry lists 14 Virus Diseases studies with AbbVie as lead sponsor. 0 are open to participants now and 14 have results posted.

Phase 2 3Phase 3 10No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of BelarusCompletedNCT02968173Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)CompletedNCT02738138Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus InfectionCompletedNCT02723084Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02707952Phase 3Results posted
• A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 InfectionCompletedNCT02640157Phase 3Results posted
• Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus InfectionCompletedNCT02609659Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02292719Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated CirrhosisCompletedNCT02219477Phase 3Results posted
• A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 CoinfectionCompletedNCT01939197Phase 2/3Results posted
• A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment BeforeCompletedNCT01854697Phase 3Results posted
• A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus InfectionCompletedNCT01672983Phase 2Results posted
• Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) ProgramCompletedNCT01662336Results posted
• Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical ConditionsCompletedNCT01466062Phase 3Results posted
• A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin AmericaCompletedNCT01297504Results posted